MiniMed Expands Sensor Portfolio in Europe with CE Mark for MiniMed™ 780G System with Instinct Sensor

MiniMed Group, Inc. (MiniMed), a global provider of integrated insulin delivery technologies, has received CE (Conformité Européenne) Mark approval for the use of the MiniMed™ 780G system with the Instinct sensor developed by Abbott. The approval expands the range of compatible sensors available for the company’s automated insulin delivery platform.

"At MiniMed, every advancement begins with listening to the needs of people living with diabetes," said Que Dallara, CEO of MiniMed. "By offering more sensor flexibility within a fully integrated system — backed by the proven clinical outcomes of our MiniMed™ 780G system1,2,3,4 — we're helping lighten the burden of daily management and giving individuals the freedom to choose what works best for them."

MiniMed™ 780G system now compatible with three sensors
The MiniMed™ 780G system is already compatible with the Guardian™ 4 and Simplera Sync™ sensors, both of which offer up to seven days of wear time. The newly approved Instinct sensor, developed exclusively by Abbott for MiniMed’s automated insulin delivery (AID) system, is described as the world's smallest, thinnest and most discreet continuous glucose monitoring (CGM) sensor and offers up to 15 days of wear time.

With this addition, users of the MiniMed™ 780G system can choose between 7-day and 15-day sensors, allowing greater flexibility based on individual preferences and lifestyle needs.

MiniMed expects the commercial launch of the MiniMed™ 780G system with the Instinct sensor in the first European countries during the summer of 2026. The company will also present the complete system at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2026) taking place in Barcelona from March 11–14, 2026.

In Europe, the MiniMed™ 780G system is indicated for individuals aged two years and older with insulin-requiring diabetes (type 1 and type 2) whose total daily insulin dose is six units or more. The system is also CE marked for use during pregnancy.

In the United States, the MiniMed™ 780G system is approved for individuals aged seven years and older with type 1 diabetes and adults aged 18 years and older with insulin-requiring type 2 diabetes. Clinical trials are currently underway to evaluate the system for children aged two to six years. The MiniMed™ 780G system has not yet been approved for use during pregnancy by the FDA.